Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

DNMT1 and DNMT3B regulate tumorigenicity of human prostate cancer cells by controlling RAD9 expression through targeted methylation

Carcinogenesis(2020)10.1093/carcin/bgaa088Source: DataRank Database

DNMT1 and DNMT3B regulate tumorigenicity of human prostate cancer cells by controlling RAD9 expression through targeted methylation is a research paper published in Carcinogenesis (2020). On theSindex it has a DataRank of 0. It has been cited 48 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access48 citations

Download PDF

Cite:

Linked data & code

refseq doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.72)OA: greenTopics (54)Linked Datasets (12)DataCite Reuse (12)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Kevin M. Hopkins,Richard A. Friedman ORCID,Joshua D. Bernstock ORCID,Constantinos G. Broustas ORCID,Howard B. Lieberman

Live enrichment

PubMed:32780107 PMC:PMC7905840 OpenAlex:https://openalex.org/W3048518710

National Institutes of Health

Grant: CA130536

National Center for Advancing Translational Sciences

Grant: UL1 TR001873

National Cancer Institute Cancer Center

Grant: P30CA013696

NCI NIH HHS

Grant: R01 CA130536

FWCI

1.72

Citation Percentile

0.8%

Citation Trend

2021

2022

2023

2024

2025

2026

greenLicense: https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7905840

publisherhttp://academic.oup.com/carcin/advance-article-pdf/doi/10.1093/carcin/bgaa088/33717696/bgaa088.pdf

publisherhttp://academic.oup.com/carcin/article-pdf/42/2/220/36357189/bgaa088.pdf

journalhttps://doi.org/10.1093/carcin/bgaa088

Fields of Study

Epigenetics and DNA MethylationCancer-related gene regulationCancer-related molecular mechanisms researchAnimalsCarcinogenesisCell Cycle ProteinsCell Line, TumorDNA (Cytosine-5-)-Methyltransferase 1DNA (Cytosine-5-)-MethyltransferasesDNA MethylationEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansMaleMiceProstateProstatic NeoplasmsXenograft Model Antitumor AssaysDNA Methyltransferase 3B

MeSH Terms

DNA (Cytosine-5-)-Methyltransferase 1DNA Methyltransferase 3BAnimalsDNA (Cytosine-5-)-MethyltransferasesHumansMaleProstateProstatic NeoplasmsGene Expression Regulation, NeoplasticCell Cycle ProteinsDNA MethylationXenograft Model Antitumor AssaysEpigenesis, GeneticCell Line, TumorMiceCarcinogenesis

Keywords

DU145Cancer researchDNA methylationProstate cancerMethyltransferaseCarcinogenesisLNCaPBiologyDNMT1Ectopic expressionMethylationTumor suppressor geneCancer cellCancerGene knockdownGene expressionCell cultureGeneticsGene

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of RBM14 as a novel epigenetic-activated tumor oncogene is implicated in the reprogramming of glycolysis in lung cancer

10.6084/m9.figshare.22637945.v1figshare

Additional file 1 of RBM14 as a novel epigenetic-activated tumor oncogene is implicated in the reprogramming of glycolysis in lung cancer

10.6084/m9.figshare.22637945figshare

Additional file 2 of RBM14 as a novel epigenetic-activated tumor oncogene is implicated in the reprogramming of glycolysis in lung cancer

10.6084/m9.figshare.22637948figshare

Additional file 2 of RBM14 as a novel epigenetic-activated tumor oncogene is implicated in the reprogramming of glycolysis in lung cancer

10.6084/m9.figshare.22637948.v1figshare

Additional file 4 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.26724362.v1figshare

Additional file 4 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.26724362figshare

Additional file 2 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.25885157figshare

Additional file 2 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.25885157.v1figshare

Additional file 1 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.25884953figshare

Additional file 3 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.26724359figshare

Additional file 1 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.25884953.v1figshare

Additional file 3 of Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer

10.6084/m9.figshare.26724359.v1figshare